Heron Therapeutics' Q1 revenue falls as oncology sales drop

Heron Therapeutics

11/05/2026 13:12

Overview

US biotech firm's Q1 net revenue fell yr/yr to $34.7 mln

Acute care franchise revenue grew 32% yr/yr, offset by oncology sales decline

Company reaffirmed 2026 guidance

Outlook

Heron reaffirms 2026 full-year net revenue guidance of $173 mln to $183 mln

Company maintains 2026 adjusted EBITDA guidance of $10 mln to $20 mln

Result Drivers

ACUTE CARE GROWTH - Revenue from the Acute Care franchise rose 32% yr/yr, driven by higher demand for ZYNRELEF and APONVIE

ONCOLOGY REVENUE DECLINE - Oncology Supportive Care revenue fell yr/yr, reflecting lower CINVANTI and SUSTOL sales

Company press release: ID:nGNXt6hYB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.04
Q1 Net Income
-$8.11 mln
Q1 Income From Operations
-$4.77 mln
Q1 Operating Expenses
$28.84 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Heron Therapeutics Inc is $4.00, about 230.6% above its May 8 closing price of $1.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)